Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TXN | P10599 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799372 | 0.93 | HPGDS (0.61) | HPGDSMEN1KMT2AHPGDRAB9A | |
| SCHEMBL1801405 | 0.92 | HPGDS (0.51) | HPGDSMEN1KMT2AHPGDRAB9A | |
| SCHEMBL1800879 | 0.91 | HPGDS (0.55) | HPGDSMEN1KMT2AHPGDRAB9A | |
| SCHEMBL1798163 | 0.88 | HPGDS (0.53) | HPGDSMEN1KMT2AHPGDRAB9A | |
| SCHEMBL1801603 | 0.88 | HPGDS (0.50) | HPGDSMEN1KMT2AHPGDRAB9A | |
| SCHEMBL1799382 | 0.88 | HPGDS (0.52) | HPGDSHPGDALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL1797249 | 0.85 | HPGDS (0.49) | HPGDSMEN1KMT2AHPGDRAB9A | |
| SCHEMBL1801409 | 0.85 | HPGDS (0.60) | HPGDSMEN1KMT2AHPGDRAB9A | |
| SCHEMBL1799658 | 0.84 | HPGDS (0.48) | HPGDSMEN1KMT2AHPGDRAB9A | |
| SCHEMBL1799661 | 0.84 | HPGDS (0.48) | HPGDSMEN1KMT2APOLBHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1911755-B1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-1911755-B1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7951956-B2 | Benzoimidazole compound capable of inhibiting prostaglandin D synthetase | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951956-B2 | Benzoimidazole compound capable of inhibiting prostaglandin D synthetase | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951956-B2 | Benzoimidazole compound capable of inhibiting prostaglandin D synthetase | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1911755-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911755-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | PTGS1, PTGIS, PTGES | HPGDS 5/4885MEN1 3586/4885KMT2A 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.